To compare the therapeutic efficacy of VV-Control plus anti-TIGIT antibody (α-TIGIT) with VV-α-TIGIT monotherapy, 4T1 tumor-bearing mice were treated with VV-Control or VV-α-TIGIT every other day for 3 times via intratumoral injection. This evidence concerns the gene TIGIT and neoplasm.